ERBB2 and neoplasm: Binding to HER2 across a range of expression levels, formation of receptor clusters, and receptor internalization resulting in HER2 downregulation, inhibits growth factor‐dependent and growth factor‐independent tumour‐cell proliferation and activates immune‐mediated responses.